RemovedMD&A
Corporate and other includes unallocated corporate overhead, unallocated foreign currency exchange gains and losses, last-in first-out (“LIFO”) inventory valuation reserve adjustments, loss on early extinguishment of debt, unallocated restructuring, impairment and plant closing costs, nonoperating income and expense and gains and losses on the disposition of corporate assets. Adjusted EBITDA from Corporate and other for Huntsman Corporation remained the same, a loss of $163 million, for 2024 as compared to 2023. Adjusted EBITDA from Corporate and other for Huntsman International remained the same, a loss of $160 million, for 2024 as compared to 2023. The impact on adjusted EBITDA from Corporate and other resulted primarily from decreases in corporate overhead costs and unallocated foreign currency exchange losses, offset by an increase in LIFO valuation losses.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
Prepaid expenses increased by $22 million primarily due to higher prepaid information technology costs.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
Our €300 million 2025 Senior Notes are scheduled to mature on April 1, 2025. Accordingly, an approximate €306 million (approximately $320 million as of December 31, 2024) payment for the principal and the unpaid, accrued interest will be made from our available liquidity.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
On January 31, 2024, we completed the planned separation and acquisition of assets of SLIC, our manufacturing joint venture with BASF and three Chinese chemical companies. The final purchase price of the acquired assets has been determined based on an asset valuation, which was completed in the second quarter of 2024. The acquisition of the assets was funded in part with HPS issuing a U.S. dollar equivalent note payable at closing of approximately $218 million, which was repaid in full in the second quarter of 2024 using available funds at HPS. During the third quarter of 2024, we received approximately $64 million of cash from SLIC, of which $34 million was a dividend and $30 million was an interim liquidating distribution. Upon the full liquidation of the joint venture, all remaining cash of SLIC, primarily resulting from the proceeds received by SLIC, will be distributed back to the joint venture partners. We currently anticipate that approximately RMB 300 million (approximately $40 million as of December 31, 2024) will be distributed as a liquidating distribution and return of investment upon full liquidation, which we anticipate will be completed in 2025.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
On February 28, 2023, we completed the sale of our Textile Effects Business to Archroma, and during the first quarter of 2024, we finalized the purchase price valued at $597 million, which includes adjustments to the purchase price for working capital, plus the assumption of underfunded pension liabilities. During the year ended December 31, 2024, we paid cash taxes of approximately $11 million, and we expect to pay additional cash taxes of approximately $2 million and expect to pay cash for contingencies and post-closing indemnifications in future periods related to the sale of our Textile Effects Business. See “Note 4. Discontinued Operations—Sale of Textile Effects Business” to our consolidated financial statements.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
During 2020 and 2021, management implemented cost realignment and synergy plans and, in November 2022, committed to further plans to realign our cost structure with additional restructuring in Europe, including exiting and consolidating certain facilities, workforce relocation to lower cost locations and further personnel rationalization. In connection with these plans, we have achieved combined annualized cost savings and synergy benefits in excess of $280 million. Associated with these plans, we expect total cash costs of approximately $300 million (including approximately $60 million of capital expenditures) through 2026, of which we have spent approximately $275 million through the end of 2024 (including approximately $44 million of capital expenditures). Of the remaining cash costs, the majority will be payments related to our restructuring in Europe, primarily for personnel who have exited as of the end of 2023 as well as capital expenditures related to our research and development footprint, which is included in our overall future capital expenditures projections.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
On January 22, 2024, we entered into an amendment to our U.S. A/R Program that extended the scheduled maturity date of our U.S. A/R Program from July 2024 to January 2027. In addition, on January 31, 2024, we entered into an amendment to our EU A/R Program, effective as of February 15, 2024, that extended the scheduled maturity date of our EU A/R Program from July 2024 to July 2027. Aside from the extended maturity dates, these amendments to our A/R Programs secured substantially similar terms as those in the prior agreements.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
On February 6, 2025, the Louisiana Supreme Court affirmed the jury verdict and district court judgment in our favor in our long-running court battle against Praxair/Linde, one of the industrial gas suppliers to our Geismar, Louisiana MDI manufacturing site, and entered a damages award consistent with Huntsman’s expert witness testimony at trial. The case was filed after Praxair refused to maintain properly its own Geismar facility and then repeatedly failed to supply our requirements for industrial gases needed to manufacture MDI under long-term supply contracts that expired in 2013. We are evaluating our options with respect to this latest ruling which would result in a final award of approximately $42.5 million or, after adding mandatory pre-judgment and post-judgment interest approximately $65 million. Taking into account taxes and legal fees, we would expect to receive net proceeds of approximately $25 million to $30 million. We have not yet recognized the award in our consolidated statements of operations, and the timing of the resolution of this matter is uncertain.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
On September 26, 2024, Huntsman International completed a $350 million offering of its 2034 Senior Notes. Huntsman International used the net proceeds from the offering for general corporate purposes, including repayment of debt. The 2034 Senior Notes bear interest at 5.70% per year, payable semi-annually on April 15 and October 15 of each year, and will mature on October 15, 2034. For more information, see “Note 8. Debt—Direct and Subsidiary Debt—Senior Notes” to our consolidated financial statements.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RewordedMD&A
December 31, Percent change 2024 2023 2022 2024 vs 2023 2023 vs 2022 Revenues $6,036 $6,111 $8,023 Selling, general and administrative 670 671 689 — (3 Research and development 120 121 115 (1 (24 Cost of goods sold 5,170 5,205 6,477 (1 (20 Gross profit 866 906 1,546 (4 (41 Operating expenses 793 804 788 (1 2 5 Restructuring, impairment and plant closing costs 148 39 18 86 279 117 (79 Income associated with litigation matter, net (33) — — NM NM Gain on acquisition of assets, net (5) (51) — — (90 NM — Prepaid asset write-off — 71 — — (100 NM — Loss on dissolution of subsidiaries(4) subsidiaries — 39 — (100 NM Other operating (income) expense, net (18) 1 — NM — NM Total operating expenses 882 891 822 (1 8 Operating (loss) income (131) (25) 84 672 424 NM (88 Interest expense, net (79) (79) (65) (62) — 22 5 Equity in income of investment in unconsolidated affiliates 4 44 83 67 (91 (47 24 Other income (expense), net 14 21 (3) 20 NM (33 NM (Loss) income from continuing operations before income taxes (192) (39) 99 697 392 NM (86 Income tax expense (26) (61) (64) (186) (57 (5 (66 (Loss) income from continuing operations (218) (100) 35 511 118 NM (93 (Loss) income from discontinued operations, net of tax (9) (27) 118 12 (67 NM 883 Net (loss) income (227) (127) 153 523 79 NM (71 Reconciliation of net (loss) income to adjusted EBITDA(1):
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedMD&A
December 31, Percent change 2024 2023 2022 2024 vs 2023 2023 vs 2022 Revenues $6,036 $6,111 $8,023 Selling, general and administrative 667 668 686 — (3 Research and development 120 121 115 (1 (24 Cost of goods sold 5,170 5,205 6,477 (1 (20 Gross profit 866 906 1,546 (4 (41 Operating expenses 790 801 784 (1 2 5 Restructuring, impairment and plant closing costs 148 39 18 86 279 117 (79 Income associated with litigation matter, net (33) — — NM NM Gain on acquisition of assets, net (5) (51) — — (90 NM — Prepaid asset write-off — 71 — — (100 NM — Loss on dissolution of subsidiaries(4) subsidiaries — 39 — (100 NM Other operating (income) expense, net (18) 1 — NM — NM Total operating expenses 879 888 819 (1 8 Operating (loss) income (128) (22) 87 676 482 NM (87 Interest expense, net (79) (79) (65) (62) — 22 5 Equity in income of investment in unconsolidated affiliates 4 44 83 67 (91 (47 24 Other income (expense), net 14 21 (3) 19 NM (33 NM (Loss) income from continuing operations before income taxes (189) (36) 102 700 425 NM (85 Income tax expense (27) (62) (65) (188) (56 (5 (65 (Loss) income from continuing operations (216) (98) 37 512 120 NM (93 (Loss) income from discontinued operations, net of tax (9) (27) 118 12 (67 NM 883 Net (loss) income (225) (125) 155 524 80 NM (70 Reconciliation of net (loss) income to adjusted EBITDA(1):
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedMD&A
Net (loss) income $ (227 $ (127 $ 153 $ 523 Net income attributable to noncontrolling interests (57 (62 (52 (63 Business acquisition and integration (gain) expenses and purchase accounting inventory adjustments, net $ (4) $ — (4 $ 21 $ (17) 4 $ 4 $ (1) 3 $ 12 $ (2) 10 Loss (income) from discontinued operations(2) 9 — 9 38 (11) 27 (135) 17 (118 (43) 31 (12 Fair value adjustments to Venator investment, net and other tax matter adjustments — — — (12) 3 (9 5 — 5 12 — 12 Certain legal and other settlements and related expenses(3) (income) expenses, net(3) (30) 7 (23 13 (3) 10 6 (1) 5 7 (2) 5 Costs associated with the Albemarle Settlement, net — — — — — — 3 (1) 2 Loss on sale of business/assets 5 (1) 4 1 — 1 — — — — — — Loss on dissolution of subsidiaries(4) — — — 39 — 39 — — — — — — Income from transition services arrangements — — — — — — (2) — (2 Certain nonrecurring information technology project implementation costs — — — 5 (1) 4 — — — 5 (1) 4 Amortization of pension and postretirement actuarial losses 34 (4) 30 39 (3) 36 37 (6) 31 49 (11) 38 Plant incident remediation credits — — — — — — (4) 1 (3 Establishment of significant deferred tax asset valuation allowances(7) allowances, net(7) — 1 1 — 23 23 — 14 14 — 49 49 Income tax settlement related to U.S.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedMD&A
December 31, December 31, (Decrease) Increase Percent 2025 2024 2023 increase (decrease) change Cash and cash equivalents $429 $340 $540 $(200) (37 $89 26 Accounts and notes receivable, net 677 725 753 (28) (4 (48) (7 Inventories 818 917 867 50 6 (99) (11 Prepaid expenses 94 114 92 22 24 (20) (18 Other current assets 46 29 62 (33) (53 17 59 Total current assets 2,064 2,125 2,314 (189) (8 (61) (3 Accounts payable 721 770 719 51 7 (49) (6 Accrued liabilities 458 416 395 21 5 42 10 Current portion of debt 353 325 12 313 NM 28 9 Current operating lease liabilities 57 54 46 8 17 3 6 Total current liabilities 1,589 1,565 1,172 393 34 24 2 Working capital $475 $560 $1,142 $(582) (51 $(85) (15
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedMD&A
Business acquisition and integration (gain) expenses and purchase accounting inventory adjustments, net (4) 21 4 12 EBITDA from discontinued operations(2) 9 38 (135) (43) Fair value adjustments to Venator investment, net and other tax matter adjustments — (12) 5 12 Certain legal and other settlements and related expenses(3) (income) expenses, net(3) (30) 13 6 7 Costs associated with the Albemarle Settlement, net — — 3 Loss on sale of business/assets 5 1 — — Loss on dissolution of subsidiaries(4) — 39 — — Income from transition services arrangements — — (2) Certain nonrecurring information technology project implementation costs — 5 — 5 Amortization of pension and postretirement actuarial losses 34 39 37 49 Plant incident remediation credits — — (4) Restructuring, impairment and plant closing and transition costs(5) 153 46 25 96 Adjusted EBITDA(1) $278 $417 $475 $1,158 (33 (12 (59 Net cash provided by operating activities from continuing operations $299 $285 $253 $895 5 13 (72 Net cash used in investing activities from continuing operations (137) (138) (42) (1,277) — 229 (97 Net cash (used in) provided by used in financing activities (72) (314) (271) 22 (77 16 NM Capital expenditures from continuing operations (173) (184) (230) (272) (6 (20 (15 Amounts attributable to Huntsman International:
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedMD&A
Business acquisition and integration (gain) expenses and purchase accounting inventory adjustments, net (4) 21 4 12 EBITDA from discontinued operations(2) 9 38 (135) (43) Fair value adjustments to Venator investment, net and other tax matter adjustments — (12) 5 12 Certain legal and other settlements and related expenses(3) (income) expenses, net(3) (30) 13 6 7 Costs associated with the Albemarle Settlement, net — — 3 Loss on sale of business/assets 5 1 — — Loss on dissolution of subsidiaries(4) — 39 — — Income from transition services arrangements — — (2) Certain nonrecurring information technology project implementation costs — 5 — 5 Amortization of pension and postretirement actuarial losses 34 39 37 49 Plant incident remediation credits — — (4) Restructuring, impairment and plant closing and transition costs(5) 153 46 25 96 Adjusted EBITDA(1) $275 $414 $472 $1,155 (34 (12 (59 Net cash provided by operating activities from continuing operations $298 $285 $251 $892 5 14 (72 Net cash (used in) provided by investing activities from continuing operations (132) (126) 309 (260) NM 5 NM Net cash used in financing activities (76) (326) (620) (994) (77 (47 (38 Capital expenditures from continuing operations (173) (184) (230) (272) (6 (20 (15 Amounts attributable to Huntsman Corporation:
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedMD&A
Other income (expense), net for the year ended December 31, 2024 The decrease was income of $21 million as compared with expense of $3 million in the 2023 period, primarily due to a decrease in losses related to the fair value adjustments to our investment in Venator, as well as income recognized during the year ended December 31, 2024 for the resolution of certain matters related to the 2017 separation of our titanium dioxide and performance additives business.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedMD&A
(7) During the years ended December 31, 2024, 2023 2025, 2024 and 2022, 2023, we established significant deferred tax asset valuation allowances of a net of $1 million ($9 million in Luxembourg, net of a release of $8 million in Germany), $23 million, million in Luxembourg and Germany and $14 million and $49 million, respectively, in Germany, Luxembourg, the U.K. and the Netherlands. U.K., respectively.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in net cash provided by operating activities from continuing operations during 2024 2025 compared with 2023 2024 was primarily attributable to an increase of $42 million in dividends received from unconsolidated subsidiaries and a net cash inflow of $29 $168 million related to changes in operating assets and liabilities for 2024 2025 as compared with 2023, partially 2024, mostly offset by a decrease of $37 $84 million in dividends received from unconsolidated subsidiaries and a decrease of $71 million in operating (loss) income loss from continuing operations adjusted for noncash activities as noted in our consolidated statements of cash flows.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedMD&A
In addition, in 2024 2025 we recognized discrete tax expenses expense for valuation allowance establishments of approximately $5 million, which is lower than the tax expense recognized in 2024 for settlement of U.S. tax reform items of approximately $5 million and discrete establishments of valuation allowances of approximately $29 million, which were greater than the valuation allowance net establishments of approximately $16 million in 2023. million.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedMD&A
(3) Certain legal Commitments and other settlements Contingencies—Legal Matters” to our consolidated financial statements) and related expenses for the year ended December 31, 2024 includes approximately $10 million related to the settlement of a claim in connection with a commercial dispute. dispute during the year ended December 31, 2024.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedMD&A
Net income attributable to noncontrolling interests (57) (62) (52) (63) (8 19 (17 Interest expense, net from continuing operations 79 79 65 62 — 22 5 Income tax expense from continuing operations 26 61 64 186 (57 (5 (66 Income tax (benefit) expense from discontinued operations — (11) 17 19 (100 NM (11 Depreciation and amortization of continuing operations 287 289 278 281 (1 4 (1 Depreciation and amortization of discontinued operations — — 12 — (100 Other adjustments:
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new